The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant nivolumab plus ipilimumab in localized dMMR/MSI-high gastric/GEJ adenocarcinoma is linked to 4-year OS of 84.1% in 32 French trial patients.
- Why it matters: Long-term outcomes and event timing are needed to judge whether adding immune checkpoint blockade to surgery improves survival for localized dMMR/MSI-high gastric or GEJ cancer.
- What they did: In the French, multicenter, single-arm phase 2 NEONIPIGA trial (cT2-T4NXM0, NCT04006262), patients received 6 cycles nivolumab plus 2 cycles ipilimumab, then surgery, with adjuvant nivolumab; EFS and OS were analyzed with median follow-up of 48.3 months.
- The result: Among 31 surgery-eligible patients, 4-year EFS was 83.5%, and 17 of 29 achieved pCR; all non-surgical patients had clinical complete response, with no additional late toxic effects reported.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.